Your browser doesn't support javascript.
loading
Netrin-1 feedforward mechanism promotes pancreatic cancer liver metastasis via hepatic stellate cell activation, retinoid, and ELF3 signaling.
Dudgeon, Crissy; Casabianca, Anthony; Harris, Chris; Ogier, Charline; Bellina, Mélanie; Fiore, Stephany; Bernet, Agnes; Ducarouge, Benjamin; Goldschneider, David; Su, Xiaoyang; Pitarresi, Jason; Hezel, Aram; De, Subhajyoti; Narrow, Wade; Soliman, Fady; Shields, Cory; Vendramini-Costa, Debora Barbosa; Prela, Orjola; Wang, Lan; Astsaturov, Igor; Mehlen, Patrick; Carpizo, Darren R.
  • Dudgeon C; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.
  • Casabianca A; Department of Surgery, Division of Surgical Oncology, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA; Wilmot Cancer Center, University of Rochester, Rochester, NY, USA.
  • Harris C; Department of Surgery, Division of Surgical Oncology, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA; Wilmot Cancer Center, University of Rochester, Rochester, NY, USA.
  • Ogier C; Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA.
  • Bellina M; Apoptosis, Cancer and Development Laboratory - Equipe labellisée "La Ligue," LabEx DEVweCAN, Institut Convergence PLAsCAN, Centre de Recherche en Cancérologie de Lyon (CRCL), INSERM U1052-CNRS UMR5286, Université de Lyon, Université Claude Bernard Lyon 1, Centre Léon Bérard, 69008 Lyon, France; Netr
  • Fiore S; Apoptosis, Cancer and Development Laboratory - Equipe labellisée "La Ligue," LabEx DEVweCAN, Institut Convergence PLAsCAN, Centre de Recherche en Cancérologie de Lyon (CRCL), INSERM U1052-CNRS UMR5286, Université de Lyon, Université Claude Bernard Lyon 1, Centre Léon Bérard, 69008 Lyon, France.
  • Bernet A; Apoptosis, Cancer and Development Laboratory - Equipe labellisée "La Ligue," LabEx DEVweCAN, Institut Convergence PLAsCAN, Centre de Recherche en Cancérologie de Lyon (CRCL), INSERM U1052-CNRS UMR5286, Université de Lyon, Université Claude Bernard Lyon 1, Centre Léon Bérard, 69008 Lyon, France; Netr
  • Ducarouge B; Netris Pharma, 69008 Lyon, France.
  • Goldschneider D; Netris Pharma, 69008 Lyon, France.
  • Su X; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.
  • Pitarresi J; Department of Medicine, Division of Hematology/Oncology, University of Massachusetts, Worcester, MA, USA.
  • Hezel A; Department of Medicine, Division of Medical Oncology, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA.
  • De S; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.
  • Narrow W; Department of Surgery, Division of Surgical Oncology, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA; Wilmot Cancer Center, University of Rochester, Rochester, NY, USA.
  • Soliman F; Rutgers Robert Wood-Johnson Medical School, New Brunswick, NJ, USA.
  • Shields C; Wilmot Cancer Center, University of Rochester, Rochester, NY, USA.
  • Vendramini-Costa DB; Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA.
  • Prela O; Department of Surgery, Division of Surgical Oncology, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA.
  • Wang L; Department of Pathology and Laboratory Medicine, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA.
  • Astsaturov I; Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA.
  • Mehlen P; Apoptosis, Cancer and Development Laboratory - Equipe labellisée "La Ligue," LabEx DEVweCAN, Institut Convergence PLAsCAN, Centre de Recherche en Cancérologie de Lyon (CRCL), INSERM U1052-CNRS UMR5286, Université de Lyon, Université Claude Bernard Lyon 1, Centre Léon Bérard, 69008 Lyon, France; Netr
  • Carpizo DR; Department of Surgery, Division of Surgical Oncology, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA; Wilmot Cancer Center, University of Rochester, Rochester, NY, USA. Electronic address: darren_carpizo@urmc.rochester.edu.
Cell Rep ; 42(11): 113369, 2023 11 28.
Article en En | MEDLINE | ID: mdl-37922311
ABSTRACT
The biology of metastatic pancreatic ductal adenocarcinoma (PDAC) is distinct from that of the primary tumor due to changes in cell plasticity governed by a distinct transcriptome. Therapeutic strategies that target this distinct biology are needed. We detect an upregulation of the neuronal axon guidance molecule Netrin-1 in PDAC liver metastases that signals through its dependence receptor (DR), uncoordinated-5b (Unc5b), to facilitate metastasis in vitro and in vivo. The mechanism of Netrin-1 induction involves a feedforward loop whereby Netrin-1 on the surface of PDAC-secreted extracellular vesicles prepares the metastatic niche by inducing hepatic stellate cell activation and retinoic acid secretion that in turn upregulates Netrin-1 in disseminated tumor cells via RAR/RXR and Elf3 signaling. While this mechanism promotes PDAC liver metastasis, it also identifies a therapeutic vulnerability, as it can be targeted using anti-Netrin-1 therapy to inhibit metastasis using the Unc5b DR cell death mechanism.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias Pancreáticas / Carcinoma Ductal Pancreático / Neoplasias Hepáticas Límite: Humans Idioma: En Año: 2023 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias Pancreáticas / Carcinoma Ductal Pancreático / Neoplasias Hepáticas Límite: Humans Idioma: En Año: 2023 Tipo del documento: Article